patent expiry
Losing patent protection on a product, letting generics and biosimilars take its sales.
Exposure · 10 companies
ABBV AbbVie
Exposed“As products lose exclusivity, generic and biosimilar competition may accelerate erosion.”
- Revenue$61.2BYoY +8.6%
- Net income$4.2BYoY −1.2%
- Revenue$17.4BYoY +10.3%
- Net income$4.2Bvs $186.0M year ago
AMGN Amgen
Exposed“For example, our patents for RANKL antibodies, including sequences, for Prolia and XGEVA expired in February 2025 in the United States and in November 2025 in select countries in Europe, and we expect accelerated sales erosion driven by increased competition, as multiple biosimilars have launched in the United States and ROW.”
- Revenue$36.8BYoY +10.0%
- Net income$7.7BYoY +88.5%
- Revenue$10.4BYoY +8.5%
- Net income$3.9BYoY +20.1%
BMY Bristol-Myers Squibb
Exposed“Upon the expiration or loss of market exclusivity on a product, we can lose the major portion of that product's revenue in a very short period of time.”
- Revenue$48.2BYoY −0.2%
- Net income$7.1Bvs −$8.9B year ago
- Revenue$13.1BYoY +6.9%
- Net income$2.2BYoY −1.8%
GILD Gilead Sciences
Exposed“Patents, licenses, trade secrets, and successful defense against generic challenges are central to Gilead’s business.”
- Revenue$8.3BYoY +6.8%
- Net income$2.4BYoY −20.4%
JNJ Johnson & Johnson
Exposed“Loss of exclusivity can lead to substantial sales declines for Innovative Medicine products as generics and biosimilars enter.”
- Revenue$94.2BYoY +6.0%
- Net income$26.8BYoY +90.6%
- Revenue$25.4BYoY +5.9%
- Net income$210.0MYoY −95.9%
LLY Eli Lilly and Company
Exposed“Loss of effective patent protection for pharmaceuticals can result in the loss of effective market exclusivity for the product, often leading to a severe and rapid decline in revenues for the product.”
- Revenue$65.2BYoY +44.7%
- Net income$20.6BYoY +94.9%
- Revenue$24.4BYoY +38.6%
- Net income$6.5BYoY +15.5%
LYCA Lycia Therapeutics, Inc.
Exposed“Applications may not issue, patents may be narrow, challenged, invalidated, designed around or expire after development consumes much of their term.”
MRK Merck & Co.
Exposed“Generic and biosimilar competition, stronger branded alternatives, patent challenges, and varying intellectual-property protections across countries could reduce sales, sometimes rapidly after exclusivity ends.”
- Revenue$65.0BYoY +1.3%
- Net income$18.3BYoY +6.6%
- Revenue$18.1BYoY +4.7%
- Net income$5.1BYoY −12.4%
PFE Pfizer
Exposed“The loss, expiration or invalidation of intellectual property rights, patent litigation settlements and judgments and the expiration of co-promotion and licensing rights can have a material adverse effect on our revenues.”
- Revenue$62.6BYoY −1.6%
- Net income$7.8BYoY −3.2%
- Revenue$16.6BYoY −0.4%
- Net income$3.2BYoY −8.4%
REGN Regeneron Pharmaceuticals
Exposed“EYLEA’s U.S. regulatory exclusivity expired in May 2024, and biosimilars have launched in the U.S. and certain international markets.”
- Revenue$5.1BYoY +36.3%
- Net income$1.9BYoY +33.5%
No companies have a recent 8-K matching these events.
No companies in the selected roles.